Accueil > Information > Points forts

Points forts

2025-12-05

November Literature Highlights | Publications Featuring abinScience Products

In November 2025, abinScience’s high-quality antibodies and recombinant proteins enabled five significant publications in leading journals including Cell Genomics (IF 9.0) and Oncogene (IF 7.3). Key breakthroughs span colorectal cancer immunotherapy through non-canonical neoantigens, circCLASP1-driven macrophage polarization in breast cancer, Paris polyphylla saponins enhancing GPX4 inhibitor efficacy, Gracillin’s protection against liver ischemia-reperfusion injury, and GC7 improving pancreatic β-cell survival during islet transplantation. From critical HLA-I immunopeptidomics reagents and SPR-validated GRB2 protein to apoptosis-regulating Bcl-2 antibodies and hypusine-specific detection tools, abinScience’s products served as cornerstone reagents driving mechanistic insights and therapeutic innovation across oncology, immunology, and regenerative medicine.
2026-03-31

abinScience Supports Zhejiang University Team: NbPro Reveals Liquid-to-Solid Phase Transition of NELF Condensates in Heat Stress Transcriptional Recovery

The Lu Huasong team at Zhejiang University published in Molecular Cell the development of NbPro, a novel nanobody-based proximity labeling technique that overcomes limitations of traditional methods. Using NbPro, they identified HSPA1A and DNAJB1 as core molecular chaperones that maintain the liquid-like dynamics and reversibility of heat stress-induced NELF condensates. Through binding to the NELFA tentacle domain and regulating phosphorylation cycles, these chaperones stabilize RNA Pol II promoter-proximal pausing, prevent aberrant escape of immature Pol II, and ensure faithful and efficient transcriptional recovery after heat stress. The study uncovers the HSF1–HSPA1A/DNAJB1–NELF axis as a key mechanism for transcriptional adaptation and quality control under stress, with abinScience providing Benzonase nuclease experimental support.
2026-03-31

FungiGuard: AI Unlocks Hidden Plant Antifungal Peptides for Sustainable Crop Protection

Discover how Shanghai Jiao Tong University's FungiGuard AI model identifies novel antifungal peptides (AFPs) from plant genomes like Arabidopsis, validates AtcAFP5's strong activity against gray mold, and paves the way for eco-friendly fungal disease control in sustainable agriculture. Supported by abinScience antibodies.
2026-02-11

December Literature Highlights | Publications Featuring abinScience Products

In December 2025, several high-impact studies leveraging abinScience's high-purity recombinant proteins and antibodies were published in prestigious journals like PNAS and American Journal of Physiology-Cell Physiology. These include innovative engineering of antigen-presenting vesicles (APVs) for selective T cell stimulation in cell-free immunotherapy, and the use of GC7 to enhance pancreatic beta cell tolerance to ischemia/reperfusion injury, potentially improving islet transplantation outcomes for diabetes. abinScience products played crucial roles in validating key mechanisms, highlighting their value in advancing immunology and metabolic disease research.
2026-02-11

Targeting SAA: A Novel Immunotherapy Strategy to Reshape the Lung Cancer Immune Microenvironment

A recent study published in Frontiers in Immunology reveals how tumor-derived serum amyloid A (SAA) suppresses anti-tumor immunity in lung cancer by binding to CD36 on antigen-presenting cells (APCs), inhibiting dendritic cell and macrophage activation, promoting M2 polarization, and impairing CD8+ T cell recruitment and function. SAA-neutralizing antibodies effectively reverse this immunosuppression, restoring APC function and enhancing T cell-mediated tumor killing in both in vitro and in vivo models. These findings identify SAA-CD36 signaling as a promising new therapeutic target to overcome immunotherapy resistance in lung cancer.
2025-10-29

August Literature Highlights | Publications Featuring abinScience Products

In August, abinScience facilitated groundbreaking studies published in top journals like Angiogenesis and Redox Biology, advancing research in kidney ischemia/reperfusion injury, skin wound healing, and bacterial morphogenesis. Key findings include the role of eIF5A hypusination in reducing kidney damage, Ang2’s inhibition of wound healing via FGFR2 signaling, and BacA’s regulation of stalk formation in Asticcacaulis biprosthecum. abinScience’s high-purity antibodies and proteins were instrumental in these discoveries, supporting critical experiments in disease research and target identification.
2025-12-05

abinScience Powers Breakthrough Discovery: Microglial Lipid Metabolism Reprogramming as a Novel Therapeutic Target for Neuropathic Pain

Neuropathic pain (NP) remains a major clinical challenge due to persistent neuroinflammation and synaptic imbalance in the spinal dorsal horn. Here, we demonstrate that the critical role of the HDAC3-FOXA2-CPT1A signaling axis in microglial lipid metabolic reprogramming during NP. Using the spared nerve injury (SNI) mouse model and LPS-stimulated primary microglia, we found that nerve injury markedly downregulates FOXA2 via HDAC3-mediated deacetylation, resulting in reduced CPT1A suppression, lipid droplet accumulation, mitochondrial dysfunction, pro-inflammatory polarization, and defective synaptic pruning. Overexpression of FOXA2 or pharmacological inhibition of HDAC3 restored CPT1A-dependent fatty acid oxidation, normalized lipid homeostasis, rescued mitochondrial function, promoted anti-inflammatory phenotype switching, and re-established excitatory/inhibitory synaptic balance, ultimately producing robust analgesic effects.
2025-12-10

abinScience Facilitates Naozhenning's Targeting Neuronal Ferroptosis: Quercetin-Luteolin-HMOX1 Axis

This study is the first to systematically demonstrate that ferroptosis plays a central, dynamic role in the neuropathology of repeated mild traumatic brain injury (rmTBI), peaking 48 h–7 d post-injury in a rat multiple cerebral concussion (MCC) model. The traditional Chinese herbal compound Naozhenning significantly ameliorates cognitive deficits and hippocampal neuronal loss, with low-dose administration showing optimal efficacy. Through integrated LC-HRMS, network pharmacology, molecular docking, and SPR validation, quercetin and luteolin were identified as the core bioactive components that specifically bind HMOX1 to inhibit neuronal ferroptosis. These findings reveal a novel rmTBI pathological mechanism and provide a mechanistic basis and clinical translation pathway for ferroptosis-targeted neuroprotection using traditional Chinese medicine.
2025-12-05

abinScience Now Speaks Your Language – Multilingual Website Live

abinScience, a strategic brand under AtaGenix, has launched a multilingual website experience so global researchers can browse recombinant proteins, antibodies, assay kits and custom development services in their preferred language. The update localizes key pages, navigation and support content while keeping core scientific data consistent across all regions.
2025-11-05

July Literature Highlights | Publications Featuring abinScience Products

Recent studies published in high-impact journals like The Journal of Infectious Diseases and Clinical Pharmacokinetics highlight the pivotal role of abinScience’s high-quality tools in advancing protein and antibody research. Investigations into respiratory syncytial virus (RSV) fusion protein epitope-specific antibodies reveal their neutralizing potential, informing vaccine and monoclonal antibody development. In lung cancer, therapeutic drug monitoring (TDM) optimizes durvalumab dosing, enhancing cost-effectiveness. Additionally, functionalized hydrogel nanovials improve T cell capture for immunotherapy. These findings, supported by abinScience’s antibodies and ELISA kits, underscore breakthroughs in disease mechanism exploration and personalized medicine.
2025-11-05

June Literature Highlights | Publications Featuring abinScience Products

In June, abinScience-supported studies published in top journals like Aging Cell and Scientific Reports advanced research in Alzheimer’s disease, infectious diseases, and anti-doping. Key findings include the role of Galectin-9 in driving amyloid-β pathology, the identification of ACTG1 as a receptor for Mycoplasma penetrans P35 lipoprotein, the development of a sensitive LC-HRMS/MS method for detecting activin receptor inhibitors in doping control, and the enhancement of anti-HER2 therapy via T-cell activation in gastric cancer. abinScience’s high-purity recombinant proteins and antibodies were instrumental in these breakthroughs, highlighting their impact on neurodegenerative diseases, infection mechanisms, and anti-doping strategies.
2025-11-05

May Literature Highlights | Publications Featuring abinScience Products

In May, abinScience-supported research published in Nature Communications and Chemical Engineering Journal advanced biotechnology and healthcare through studies on cancer biomarker detection, antiviral nanobody development, and rapid infectious disease diagnostics. Key achievements include ultrapotent single-domain antibodies neutralizing SARS-CoV-2 variants, an ultrasensitive electrochemical biosensor for simultaneous detection of monkeypox virus antigens M1R and A29, and a sodium alginate gel-based sensor for ultra-trace detection of ovarian cancer biomarker HE4. abinScience’s high-quality proteins and antibodies were critical to these breakthroughs, highlighting their role in addressing global health challenges.

Obtenir un devis gratuit